Heron Patrick J
SEC CIK 1365617 · EDGAR
BoughtSold
Most active insiders at ARQT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Watanabe Todd | See Remarks, Dir | — | $5.32M |
| 2 | Welgus Howard G. | Dir | — | $2.43M |
| 3 | Matsuda Masaru | See Remarks | — | $2.21M |
| 4 | Burnett Patrick | See Remarks | — | $2.02M |
| 5 | Leonard Keith R | Dir | — | $997.1K |
| 6 | Curran Terrie | Dir | — | $984.0K |
| 7 | Edwards Larry Todd | See Remarks | — | $968.4K |
| 8 | Krishnamohan Neha | Dir | — | $939.5K |
| 9 | LIN SUE-JEAN | Dir | — | $898.5K |
| 10 | Gilbert Halley E | Dir | — | $455.5K |
| 14 | Heron Patrick J | Dir | — | — |
Transactions 27
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-09 21:21 | 2026-06-05 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | A - Grant | $0.00 | +5,778 | 32.2K | +22% | $0 |
| I | 2026-01-27 | 2026-01-23 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | J - Other | — | +159.3K | 327.6K | +95% | — |
| I | 2026-01-27 | 2026-01-23 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $68.48 | +131.4K | 459.0K | +40% | +$9.00M |
| I | 2025-06-17 | 2025-06-13 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.08 | +2,646 | 27.4K | +11% | +$34.6K |
| D | 2025-06-16 | 2025-06-12 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir, 10% | A - Grant | $0.00 | +7,609 | 26.4K | +40% | $0 |
| MI | 2025-06-06 | 2025-06-04+ | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.33 | +2,268 | 24.4K | +10% | +$30.2K |
| D | 2025-06-02 | 2025-05-29 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | M - OptEx | — | +5,703 | 5,703 | New | — |
| MI | 2025-05-23 | 2025-05-21+ | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.65 | +5,040 | 22.5K | +29% | +$68.8K |
| I | 2025-05-19 | 2025-05-15 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.62 | +2,520 | 17.5K | +17% | +$34.3K |
| MI | 2025-05-15 | 2025-05-13+ | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.76 | +8,674 | 8,674 | New | +$119.4K |
| I | 2025-05-13 | 2025-05-09 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.60 | +6,300 | 6,300 | New | +$85.7K |
| MI | 2025-03-18 | 2025-03-14+ | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $44.10 | +549 | 168.7K | +0.3% | +$24.2K |
| MI | 2025-03-12 | 2025-03-10+ | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $43.30 | +2,298 | 166.6K | +1% | +$99.5K |
| MI | 2025-03-10 | 2025-03-06+ | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $43.68 | +1,915 | 165.8K | +1% | +$83.7K |
| MI | 2025-03-06 | 2025-03-04+ | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $45.40 | +1,602 | 163.6K | +1.0% | +$72.7K |
| I | 2024-09-20 | 2024-09-18 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $37.40 | +115 | 162.3K | +0.1% | +$4,301 |
| DI | 2024-09-17 | 2024-09-16 | MBX | MBX Biosciences, Inc. | Heron Patrick J | Dir, 10% | P - Purchase | $16.00 | +625.0K | 4.55M | +16% | +$10.00M |
| DI | 2024-09-17 | 2024-09-16 | MBX | MBX Biosciences, Inc. | Heron Patrick J | Dir, 10% | C - Cnv Deriv | — | +3.93M | 3.93M | New | — |
| I | 2024-09-10 | 2024-09-06 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $41.58 | +230 | 162.2K | +0.1% | +$9,563 |
| D | 2024-06-18 | 2024-06-14 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir, 10% | A - Grant | $0.00 | +10.1K | 18.8K | +117% | $0 |
| I | 2024-03-06 | 2024-03-04 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $9.50 | +21.1K | 8.79M | +0.2% | +$200.0K |
| I | 2023-11-14 | 2023-11-09 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $28.30 | +2,910 | 162.0K | +2% | +$82.4K |
| I | 2023-09-15 | 2023-09-13 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $31.02 | +2,625 | 159.1K | +2% | +$81.4K |
| MI | 2023-09-13 | 2023-09-11+ | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $30.43 | +8,437 | 152.7K | +6% | +$256.8K |
| I | 2023-09-05 | 2023-08-31 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir, 10% | P - Purchase | $26.25 | +148.0K | 148.0K | New | +$3.88M |
| D | 2023-06-02 | 2023-05-31 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir, 10% | A - Grant | $0.00 | +4,375 | 8,687 | +101% | $0 |
| D | 2022-06-03 | 2022-06-01 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir, 10% | A - Grant | $0.00 | +4,312 | 4,312 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations